Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Aveta Biomics Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner and is being reviewed within 1 distinct art unit. The focused nature of this prosecution suggests a specific technical inquiry. This indicates a highly concentrated prosecution footprint, where the company's current interactions with the patent office are limited to a single point of contact.
The busiest examiner for the company is PURDY, KYLE A, who is responsible for the 1 pending office action. Because all current activity is concentrated with 1 distinct examiner, the company's immediate patent strategy depends on the review of this individual. Practitioners should focus on the specific examination patterns of this examiner to navigate the pending matter effectively. Because the portfolio is limited to 1 distinct art unit, the prosecution strategy can focus on the specific rules and trends of that group. Effectively managing the 1 pending office action is critical for the company's current intellectual property objectives in the biotechnology sector. The limited scope of the portfolio allows for a deep analysis of past decisions made within the 1 distinct art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PURDY, KYLE A | 1 | 41.0% | +35.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18209360 | POLYPHARMACEUTICAL DRUG COMPOSITIONS AND RELATED METHODS | PURDY, KYLE A | 63d |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18209360 | POLYPHARMACEUTICAL DRUG COMPOSITIONS AND RELATED METHODS | PURDY, KYLE A | 1611 | §103 | Final Rejection | 63d | Pending | Jun 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial